Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Bridging Practice Gaps in Granuloma Annulare: Definitions, Comorbidities, Pathogenesis, and Emerging Treatments
Description
The speaker, a granulomatous diseases specialist, reviewed major practice gaps in granuloma annulare (GA) and described efforts to standardize care. A key issue is the lack of a consistent definition for generalized GA, which has been variably described in the literature; an expert consensus definition is now being used for research and clinical work. She emphasized that GA care also lacks a validated severity scoring system, universal comorbidity screening guidelines, a full understanding of pathogenesis, and FDA-approved therapies. To address assessment gaps, her group developed the GA Severity and Morphology Instrument, designed to measure inflammation, induration, and extent across body sites and to support both clinical communication and trials. She then discussed comorbidities, focusing on metabolic disease: studies from her clinic and external cohorts found associations between GA and prediabetes, impaired glucose tolerance, diabetes, and dyslipidemia, especially in generalized or intertriginous disease, supporting routine hemoglobin A1c testing for all GA patients and lipid screening in higher-risk patterns. On pathogenesis, spatial transcriptomics and related multi-omics work suggest GA involves mixed type 1 and type 2 immune inflammation with additional metabolic pathway activation and potential biomarkers such as IL-32, TGF-beta, and CXCL-9. Finally, she reviewed emerging treatments from updated expert algorithms, including topical roflumilast and JAK inhibitors, apremilast, and earlier use of TNF or JAK inhibitors for significantly affected generalized disease, while noting that therapeutic options remain limited and evolving.
View moreConclusions
- Granuloma annulare still suffers from major practice gaps because generalized disease lacks a universally accepted definition, standardized severity measure, and consistent terminology.
- The new GA Severity and Morphology Instrument is intended to provide a shared, validated way to track disease burden and communicate disease changes over time.
- Patients with GA appear to have clinically meaningful metabolic associations, especially with prediabetes, impaired glucose tolerance, dyslipidemia, and type 2 diabetes.
- Because prediabetes is potentially reversible, dermatologists may be able to identify and intervene on metabolic risk earlier by routinely checking HbA1c in GA patients.
- Generalized GA and intertriginous involvement may be particularly associated with dyslipidemia, supporting targeted fasting lipid screening in those subgroups.
- Spatial transcriptomics suggests GA is not only an inflammatory disorder but also involves distinct metabolic pathway activation within lesions.
- These multi-omic findings imply that metabolic dysfunction may be relevant at both the systemic and tissue levels in GA pathogenesis.
- There are still no FDA-approved treatments for GA, but updated expert algorithms increasingly support earlier use of targeted therapies such as topical JAK inhibitors, apremilast, roflumilast, TNF inhibitors, and JAK inhibitors in more severe disease.
- Overall, the presentation argues for a more standardized, metabolically informed, and earlier-intervention approach to diagnosing and managing GA.
- Dabski K, Winkelmann RK. J Am Acad Dermatol. 1989.
- Nordmann TM et al. Dermatol. 2020.
- Thornsberry LA, English JC. Am J Clin Dermatol. 2013.
- Junejo MH et al. J Invest Dermatol. 2025.
- Barbieri JS et al. JAMA Dermatol. 2021.
- Garate D et al. J Am Acad Dermatol. 2024.
- Betancourt Ponce M et al. Unpublished data, under review.
- Craver et al. Unpublished data, manuscript in preparation.
- Lika J et al. Unpublished data, manuscript in preparation.
- Foroghar T et al. Submitted data.